| Literature DB >> 27195120 |
Md Nahidul Islam1, Benjamin A Bradley2, Rhodri Ceredig1.
Abstract
After major trauma, the human immune system initiates a series of inflammatory events at the injury site that is later followed by suppression of local inflammation favoring the repair and remodeling of the damaged tissues. This local immune response involves complex interactions between resident cells such as macrophages and dendritic cells, soluble mediators such as cytokines and chemokines, and recruited cells such as neutrophils, monocytes and mesenchymal stromal cells. If of sufficient magnitude, these initial immune responses nevertheless have systemic consequences resulting in a state called post-traumatic immunosuppression (PTI). However, controversy exists regarding the exact immunological changes occurring in systemic compartments triggered by these local immune responses. PTI is one of the leading causes of post-surgical mortality and makes patients vulnerable to hospital-acquired infections, multiple organ failure and many other complications. In addition, hemorrhage, blood transfusion, immunesenescence and immunosuppressant drugs aggravate PTI. PTI has been intensively studied, but published results are frequently cloudy. The purpose of this review is to focus on the contributions made by different responsive modalities to immunosuppression following sterile trauma and to try to integrate these into an overall scheme of PTI.Entities:
Year: 2016 PMID: 27195120 PMCID: PMC4855263 DOI: 10.1038/cti.2016.13
Source DB: PubMed Journal: Clin Transl Immunology ISSN: 2050-0068
Lists of studies investigating the changes in biomarker levels at the surgical wound site
| Pro-inflammatory cytokines | IL-1β | — | 2 | 10 | 1 | 13 |
| IL-2 | — | 1 | — | 1 | 2 | |
| IL-6 | — | — | 24 | — | 24 | |
| IL-12 | — | 1 | — | — | 1 | |
| IL-17 | — | 1 | — | — | 1 | |
| IFN-γ | — | 1 | — | — | 1 | |
| TNF-α | — | 4 | 6 | — | 10 | |
| Anti-inflammatory cytokines | IL-4 | — | 1 | 2 | — | 3 |
| IL-5 | — | 1 | — | — | 1 | |
| IL-10 | 1 | 1 | 3 | — | 5 | |
| IL-13 | — | 1 | — | — | 1 | |
| IL-1RA | — | — | 2 | — | 2 | |
| Chemokines | IL-8 | — | — | 12 | — | 12 |
| MCP-1 | — | — | 1 | — | 1 | |
| MIP-1α | — | 1 | — | — | 1 | |
| Others | PGE2 | — | — | 2 | — | 2 |
| sIL-6R | 1 | — | — | — | 1 | |
| C3 | — | — | 7 | — | 7 | |
| C5 | — | — | 4 | — | 4 | |
| Platelet | 4 | — | 4 | — | 8 | |
Abbreviations: ND, not detectable; IL, interleukin; sIL-6R, soluble IL-6 receptor; TNF, tumor necrosis factor.
Lists of investigations on changes in biomarker levels in postoperative venous blood following major surgery
| Pro-inflammatory cytokines | IL-1β | 3 | 21 | 3 | 5 | 32 |
| IL-2 | 7 | 4 | 1 | 1 | 13 | |
| IL-6 | — | — | 87 | 1 | 88 | |
| IL-12 | 2 | 5 | 1 | — | 8 | |
| IL-17 | — | 1 | — | 1 | 2 | |
| IFN-γ | 1 | 6 | — | — | 7 | |
| TNF-α | 5 | 23 | 6 | 5 | 39 | |
| IL-22 | — | — | 1 | — | 1 | |
| Anti-inflammatory cytokines | IL-4 | 1 | 4 | 2 | — | 7 |
| IL-5 | — | 2 | 2 | — | 4 | |
| IL-10 | — | 12 | 28 | — | 40 | |
| IL-13 | — | 4 | — | — | 4 | |
| IL-1RA | — | 3 | 8 | — | 11 | |
| Chemokines | IL-8 | — | 7 | 31 | 2 | 40 |
| MCP-1 | — | 7 | 2 | — | 9 | |
| MIP-1α | 1 | 1 | — | — | 2 | |
| DAMPs | HMGB-1 | — | 1 | 5 | — | 6 |
| HSP-27 | — | 1 | — | — | 1 | |
| HSP-60 | 1 | — | — | — | 1 | |
| HSP-70 | — | 2 | — | — | 2 | |
| Others | sIL-6R | 1 | — | — | — | 1 |
| sCD-14 | — | — | 3 | — | 3 | |
Abbreviations: DAMP, damage-associated molecular pattern; IL, interleukin; IL-1RA, IL-1 receptor antagonist; ND, not detectable; sCD-14, soluble CD-14; sIL-6R, soluble IL-6 receptor; TNF, tumor necrosis factor.
Figure 1Schematic representation of PTI after sterile trauma. This figure schematically illustrates the sequence of events following major trauma. In brief, at the local injury site, release of different DAMPs by the damaged tissues induces viable cells to secrete chemokines such as IL-8, MCP-1 and MIP-1α, and the immediate secretion of inflammatory cytokines such as TNF-α. DAMPs release results in IL-6 and TNF-α production that activate the HPE axis to release ACTH, cortisol and also PGE2. These events then trigger the secretion of anti-inflammatory biomolecules such as IL-1RA, IL-10 and sTNF-R. Later, IL-6, by the virtue of its ability to trigger the release of acute phase proteins (APPs) by the liver, indirectly involved in reducing the inflammatory events at the injured site. In parallel with the immediate release of DAMPs, inflammatory cytokines and the activities of resident immune cells, there is recruitment of neutrophils, monocytes and MSCs from the blood to the injured site. Bone marrow and spleen act as reservoirs for the egression of these cells to the site of injury via the blood. By releasing antimicrobial peptides and helping in hemostasis, damaged skin also activates inflammasomes to release DAMPs at the local site. On the other hand, ischemia–reperfusion injury associated with the surgical procedure increases HIF and ROS expression that also trigger the production of DAMPs, and thus have an additional role in recruiting immune cells to the injured site. The ultimate goal of the above events following a major trauma is tissue remodeling and promotion of wound healing.
Different immunological phases in local site of trauma and systemic circulation following sterile trauma
| Macrophages | Inflammatory M1 polarization | — | Anti-inflammatory M2 polarization | Anti-inflammatory M2 polarization |
| Monocyte | Inflammatory phenotype | Monocytosis | Differentiation into anti-inflammatory phenotype | Increase in the number of anti-inflammatory phenotypes. |
| Neutrophil | Migration into the site of injury | Neutrophilia | Apoptosis of neutrophils at the site of injury | Overall increase in number of neutrophils however probably immature or less active |
| Lymphocyte | Inflammatory Th1 pathway | Increase in lymphocyte apoptosis | Anti-inflammatory Th2 pathway | Anti-inflammatory Th2 pathway |
| NK cells | — | — | Decrease in NK cell function | Decrease in NK cell function |
| DAMPs | Elevated levels of DAMPs trigger immediate release of cytokines to facilitate inflammation | — | Elevated levels of DAMPs direct anti-inflammatory activities to favor wound healing | DAMPs direct anti-inflammatory activities to favor systemic PTI |
| HPA axis | Immediate HPA axis-mediated signaling to initiate injury induced responses | — | Cortisol- and prostaglandin-mediated suppression to favor healing | Cortisol and prostaglandin also have role in systemic suppression |
| Acute phase proteins | Immediate release as part of body's inflammatory activities | Decreased levels of positive APPs | Trigger local immunosuppressive responses | Trigger immunosuppressive responses |
| MDSCs | — | Release of MDSCs from the source | Possible recruitment of MDSCs to the site of injury to facilitate local healing | Sustained release of MDSCs probably direct towards systemic suppression |
| Cytokines | Immediate release of different inflammatory and anti-inflammatory cytokines | Continued release of anti-inflammatory cytokines, whereas downregulation of pro-inflammatory cytokine release | Reductions in inflammatory cytokines such as IL-1β, IL-2, TNF-α, IFN-γ and IL-17A, whereas elevations in anti-inflammatory IL-5 | |
Abbreviations: AAP, acute phase protein; DAMP, damage-associated molecular pattern; IL, interleukin; HPA, hypothalamus–pituitary–adrenal; MDSC, myeloid-derived suppressor cell; NK, natural killer; TNF, tumor necrosis factor.
Figure 2Measuring immune status helps in choosing appropriate immunomodulatory drug. Measuring a patient's immune status based on particular profile of specific pro- and anti-inflammatory proteins will help to indicate if the patient: (i) has a stable immune status and medication is not necessary, (ii) is at the stage of cytokine storm following trauma or infection when both pro- and anti-inflammatory cytokines rise, (iii) requires immediate attention with treatment (either immunostimulatory or immunosuppressive drug will be administered) or (iv) is not in need of medication but requires monitoring over the coming days. Knowing immune status will provide information following trauma or sepsis that can be monitored throughout the patient's recovery, thereby preventing the risk of unnecessary danger from incorrect therapy.